Abstracts Archive - Page 735 of 2607 - ACR Meeting Abstracts

Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
Abstract Number: PP02 • ACR Convergence 2021
Leveraging Digital Health Tracking to Improve Arthritis Management
Katie Roberts, Annapolis, MD
Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…
Abstract Number: PP06 • ACR Convergence 2021
Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) / My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
Michael Linn¹ and Dan Smith², ¹Relapsing Polychondritis Foundation, New York, NY, ²Relapsing Polychondritis Foundation, Canton, MI
Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
Abstract Number: PP04 • ACR Convergence 2021
Dual Roles: Thriving with SLE as a Medical Student
Chieh Lo¹ and Song-Chou Hsieh², ¹School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), ²Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
Abstract Number: PP01 • ACR Convergence 2021
Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic
Dana Guglielmo, San Diego, CA
Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
Abstract Number: 1944 • ACR Convergence 2021
Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study
Josef Smolen¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Stefan Siebert¹⁰, Elke Theander¹¹ and Laure Gossec¹², ¹Medical University of Vienna, Vienna, Austria, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹Janssen Cilag, Lund, Sweden, ¹²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
Abstract Number: 1933 • ACR Convergence 2021
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Emily Gilbert⁵, Maria Valenzuela-Almada⁶, Leanna Wise⁷, Jeffrey Sparks⁸, Tiffany Hsu⁹, Kristin D'Silva¹⁰, Naomi Patel¹⁰, Emily Sirotich¹¹, Jean Liew¹², Jonathan Hausmann¹³, Paul Sufka¹⁴, Rebecca Grainger¹⁵, Suleman Bhana¹⁶, Wendy Costello¹⁷, Zachary Wallace¹⁸, Lindsay Jacobsohn¹⁹, Anja Strangfeld²⁰, Elsa Frazão Mateus²¹, Kimme Hyrich²², Laure Gossec²³, Loreto Carmona²⁴, Saskia Lawson-Tovey²², Lianne Kearsley-Fleet²⁵, Martin Schaefer²⁶, Pedro Machado²⁷, Philip Robinson²⁸, Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Jacksonville, FL, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Boston University, Boston, MA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹⁴HealthPartners, Eagan, MN, ¹⁵University of Otago, Wellington, New Zealand, ¹⁶Crystal Run Health, Montvale, NJ, ¹⁷Irish Children's Arthritis Network, Bansha, Ireland, ¹⁸Massachusetts General Hospital, Newton, MA, ¹⁹University of California San Francisco, Antioch, CA, ²⁰Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ²¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ²²University of Manchester, Manchester, United Kingdom, ²³Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²⁴Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ²⁵Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²⁶German Rheumatism Research Center, Berlin, Germany, ²⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²⁸Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Shannan O'Hara-Levi, Monroe, NY
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
Abstract Number: PP13 • ACR Convergence 2021
CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease
Chantelle Marcial, Boston, MA
Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
Abstract Number: PP07 • ACR Convergence 2021
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Wigna Cruz, Puerto Rico
Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
Abstract Number: PP10 • ACR Convergence 2021
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Noriko Okochi¹, Eiji Oishi² and Mika Ishiguro¹, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan
Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
Abstract Number: 1929 • ACR Convergence 2021
Metabolomics Identifies Early Mechanisms of Atherogenic Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation
George Robinson¹, Kirsty Waddington¹, Junjie Peng¹, Anna Radziszewska¹, David Isenberg², Yiannis Ioannou¹, Ines Pineda-Torra¹, Coziana Ciurtin¹ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in patients with juvenile-onset systemic lupus erythematosus (JSLE) through atherosclerosis, the build-up of lipids and…
Abstract Number: 1888 • ACR Convergence 2021
Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD
Gözde Kübra Yardımcı¹, Bayram Farisogulları², Gizem Ayan¹, Levent Kilic¹, Sule Apraş Bilgen¹ and Omer Karadag³, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey, ³Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey
Background/Purpose: ACR/EULAR Classification criteria for IgG4-related disease (IgG4-RD) newly published [1]. On the other hand, four distinctive phenotypes of IgG4-RD have been described [2]. We…
Abstract Number: 1796 • ACR Convergence 2021
Early Identification of Psoriatic Arthritis with Axial Involvement Among Patients with Psoriasis: A Prospective Multicenter Study
Fabian Proft¹, Susanne Lüders², Theresa Hunter³, Gustavo Luna⁴, Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Katharina Meier⁵, Georgios Kokolakis⁵, Kamran Ghoreschi⁵ and Denis Poddubnyy⁶, ¹Charité University Medicine Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ³Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁴ICON plc, Stockholm, Sweden, ⁵Department of Dermatology, Venereology and Allergology – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: In the absence of reliable serological and/or imaging biomarkers for early psoriatic arthritis (PsA) and an existing diagnostic delay there is a need for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].